{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T01:13:16Z","timestamp":1767057196517,"version":"3.48.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07585-x","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T08:04:48Z","timestamp":1766217888000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synergistic anti-tumor effects of novel two-domain soluble Fms-like tyrosine kinase-1 and paclitaxel on three-dimensional breast cancer models: implications for targeted therapy"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9878-9462","authenticated-orcid":false,"given":"Adel Zaid I.","family":"Mutahar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renu","family":"Dayal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharathi P.","family":"Salimath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"issue":"1130","key":"7585_CR1","doi-asserted-by":"publisher","first-page":"20211033","DOI":"10.1259\/bjr.20211033","volume":"95","author":"L Wilkinson","year":"2022","unstructured":"Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022;95(1130):20211033.","journal-title":"Br J Radiol"},{"issue":"4","key":"7585_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","volume":"3","author":"C Fitzmaurice","year":"2017","unstructured":"Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, Dandona L, et al. Global, regional, and National cancer incidence, mortality, years of life lost, ears lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990\u20132015: A systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524\u201348.","journal-title":"JAMA Oncol"},{"issue":"7","key":"7585_CR3","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","volume":"15","author":"O Obidiro","year":"2023","unstructured":"Obidiro O, Battogtokh G, Akala EO. Triple negative breast cancer treatment options and limitations: future outlook. Pharmaceutics. 2023;15(7):1796.","journal-title":"Pharmaceutics"},{"issue":"1","key":"7585_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami P, Carey LA. Triple negative breast cancer: pitfalls and progress. NPJ Breast Cancer. 2022;8(1):95.","journal-title":"NPJ Breast Cancer"},{"key":"7585_CR5","doi-asserted-by":"crossref","unstructured":"Jivani A, Shinde RK. A comprehensive review of taxane treatment in breast cancer: clinical perspectives and toxicity profiles. Cureus. 2024;16(4).","DOI":"10.7759\/cureus.59266"},{"issue":"1","key":"7585_CR6","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1038\/s41598-024-82218-9","volume":"15","author":"NL Calistri","year":"2025","unstructured":"Calistri NL, Liby TA, Hu Z, Zhang H, Dane MA, Gross SM, Heiser LM. TNBC response to Paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms. Sci Rep. 2025;15(1):4294.","journal-title":"Sci Rep"},{"issue":"1","key":"7585_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KT, Guan XY. Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct Target Therapy. 2024;9(1):175.","journal-title":"Signal Transduct Target Therapy"},{"key":"7585_CR8","doi-asserted-by":"publisher","first-page":"838133","DOI":"10.3389\/fphar.2022.838133","volume":"13","author":"NM Ayoub","year":"2022","unstructured":"Ayoub NM, Jaradat SK, Al-Shami KM, Alkhalifa AE. Targeting angiogenesis in breast cancer: current evidence and future perspectives of novel anti-angiogenic approaches. Front Pharmacol. 2022;13:838133.","journal-title":"Front Pharmacol"},{"issue":"1","key":"7585_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"ZL Liu","year":"2023","unstructured":"Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Therapy. 2023;8(1):198.","journal-title":"Signal Transduct Target Therapy"},{"key":"7585_CR10","doi-asserted-by":"publisher","first-page":"175586","DOI":"10.1016\/j.ejphar.2023.175586","volume":"949","author":"S Ghalehbandi","year":"2023","unstructured":"Ghalehbandi S, Yuzugulen J, Pranjol MZ, Pourgholami MH. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. Eur J Pharmacol. 2023;949:175586.","journal-title":"Eur J Pharmacol"},{"key":"7585_CR11","doi-asserted-by":"crossref","unstructured":"Gumusay O, Vitiello PP, Wabl C, Corcoran RB, Bardelli A, Rugo HS. Strategic combinations to prevent and overcome resistance to targeted therapies in oncology. ASCO Educ Book. 2020;40:e292\u2013e308.","DOI":"10.1200\/EDBK_280845"},{"issue":"17","key":"7585_CR12","doi-asserted-by":"publisher","first-page":"9660","DOI":"10.3390\/ijms23179660","volume":"23","author":"CC van Aanhold","year":"2022","unstructured":"van Aanhold CC, Koudijs A, Dijkstra KL, Wolterbeek R, Bruijn JA, van Kooten C, Baelde HJ. The VEGF inhibitor soluble Fms-like tyrosine kinase 1 does not promote AKI-to-CKD transition. Int J Mol Sci. 2022;23(17):9660.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"7585_CR13","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1177\/1947601911423031","volume":"2","author":"M Shibuya","year":"2011","unstructured":"Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti-and pro-angiogenic therapies. Genes Cancer. 2011;2(12):1097\u2013105.","journal-title":"Genes Cancer"},{"issue":"4","key":"7585_CR14","first-page":"910","volume":"14","author":"M Kapa\u0142czy\u0144ska","year":"2018","unstructured":"Kapa\u0142czy\u0144ska M, Kolenda T, Przyby\u0142a W, Zaj\u0105czkowska M, Teresiak A, Filas V, Ibbs M, Bli\u017aniak R, \u0141uczewski \u0141, Lamperska K. 2D and 3D cell cultures\u2013a comparison of different types of cancer cell cultures. Archives Med Sci. 2018;14(4):910\u20139.","journal-title":"Archives Med Sci"},{"issue":"19","key":"7585_CR15","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.3390\/cancers15194846","volume":"15","author":"P Nayak","year":"2023","unstructured":"Nayak P, Bentivoglio V, Varani M, Signore A. Three-dimensional in vitro tumor spheroid models for evaluation of anticancer therapy: recent updates. Cancers. 2023;15(19):4846.","journal-title":"Cancers"},{"issue":"1","key":"7585_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12929-024-00994-y","volume":"31","author":"WH Abuwatfa","year":"2024","unstructured":"Abuwatfa WH, Pitt WG, Husseini GA. Scaffold-based 3D cell culture models in cancer research. J Biomed Sci. 2024;31(1):7.","journal-title":"J Biomed Sci"},{"issue":"1","key":"7585_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12943-016-0502-x","volume":"15","author":"SJ Serrano-Gomez","year":"2016","unstructured":"Serrano-Gomez SJ, Maziveyi M, Alahari SK. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer. 2016;15(1):18.","journal-title":"Mol Cancer"},{"issue":"6","key":"7585_CR18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41580-020-0237-9","volume":"21","author":"J Yang","year":"2020","unstructured":"Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, Campbell K, Cano A, Casanova J, Christofori G, Dedhar S. Guidelines and definitions for research on epithelial\u2013mesenchymal transition. Nat Rev Mol Cell Biol. 2020;21(6):341\u201352.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"7585_CR19","doi-asserted-by":"publisher","first-page":"19103","DOI":"10.1038\/srep19103","volume":"6","author":"M Zanoni","year":"2016","unstructured":"Zanoni M, Piccinini F, Arienti C, Zamagni A, Santi S, Polico R, Bevilacqua A, Tesei A. 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained. Sci Rep. 2016;6(1):19103.","journal-title":"Sci Rep"},{"issue":"1","key":"7585_CR20","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1080\/13880209.2017.1307422","volume":"55","author":"HR Raju","year":"2017","unstructured":"Raju HR, Ghosh D, Banerjee R, Salimath BP. Suppression of VEGF-induced angiogenesis and tumor growth by Eugenia jambolana, Musa paradisiaca, and coccinia indica extracts. Pharm Biol. 2017;55(1):1489.","journal-title":"Pharm Biol"},{"key":"7585_CR21","doi-asserted-by":"crossref","unstructured":"Mutahar AZ, Devaramani M, Dayal R, Saini DK, Salimath PV, Salimath BP. Vascular endothelial growth factor receptor, fms-like tyrosine kinase-1 (Flt-1), as a novel binding partner for SARS-CoV-2 Spike receptor-binding domain. Front Immunol. 2022;13:906063.","DOI":"10.3389\/fimmu.2022.906063"},{"issue":"5","key":"7585_CR22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/jgm.1309","volume":"11","author":"S Ramachandra","year":"2009","unstructured":"Ramachandra S, D\u2019Souza SS, Gururaj AE, Shaila MS, Salimath BP. Paracrine action of sFLT-1 secreted by stably\u2010transfected Ehrlich Ascites tumor cells and therapy using sFLT\u20101 inhibits Ascites tumor growth in vivo. J Gene Medicine: cross\u2010disciplinary J Res Sci Gene Transf its Clin Appl. 2009;11(5):422\u201334.","journal-title":"J Gene Medicine: cross\u2010disciplinary J Res Sci Gene Transf its Clin Appl"},{"issue":"1","key":"7585_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1741-7007-10-29","volume":"10","author":"M Vinci","year":"2012","unstructured":"Vinci M, Gowan S, Boxall F, Patterson L, Zimmermann M, Court W, Lomas C, Mendiola M, Hardisson D, Eccles SA. Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol. 2012;10(1):29.","journal-title":"BMC Biol"},{"issue":"12","key":"7585_CR24","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.3390\/pharmaceutics12121186","volume":"12","author":"B Pinto","year":"2020","unstructured":"Pinto B, Henriques AC, Silva PM, Bousbaa H. Three-dimensional spheroids as in vitro preclinical models for cancer research. Pharmaceutics. 2020;12(12):1186.","journal-title":"Pharmaceutics"},{"issue":"1","key":"7585_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neo.2014.12.004","volume":"17","author":"LB Weiswald","year":"2015","unstructured":"Weiswald LB, Bellet D, Dangles-Marie V. Spherical cancer models in tumor biology. Neoplasia. 2015;17(1):1\u20135.","journal-title":"Neoplasia"},{"issue":"1","key":"7585_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12943-025-02281-2","volume":"24","author":"Z Peng","year":"2025","unstructured":"Peng Z, Lv X, Sun H, Zhao L, Huang S. 3D tumor cultures for drug resistance and screening development in clinical applications. Mol Cancer. 2025;24(1):93.","journal-title":"Mol Cancer"},{"issue":"4","key":"7585_CR27","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.3892\/or.2015.3767","volume":"33","author":"Y Imamura","year":"2015","unstructured":"Imamura Y, Mukohara T, Shimono Y, Funakoshi Y, Chayahara N, Toyoda M, Kiyota N, Takao S, Kono S, Nakatsura T, Minami H. Comparison of 2D-and 3D-culture models as drug-testing platforms in breast cancer. Oncol Rep. 2015;33(4):1837\u201343.","journal-title":"Oncol Rep"},{"issue":"6","key":"7585_CR28","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.3390\/ijms23063036","volume":"23","author":"M Nowacka","year":"2022","unstructured":"Nowacka M, Ginter-Matuszewska B, \u015awierczewska M, Sterzy\u0144ska K, Nowicki M, Januchowski R. Effect of ALDH1A1 gene knockout on drug resistance in Paclitaxel and Topotecan resistant human ovarian cancer cell lines in 2D and 3D model. Int J Mol Sci. 2022;23(6):3036.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"7585_CR29","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s11033-024-09669-1","volume":"51","author":"M Alwahsh","year":"2024","unstructured":"Alwahsh M, Al-Doridee A, Jasim S, Awwad O, Hergenr\u00f6der R, Hamadneh L. Cytotoxic and molecular differences of anticancer agents on 2D and 3D cell culture. Mol Biol Rep. 2024;51(1):721.","journal-title":"Mol Biol Rep"},{"issue":"11","key":"7585_CR30","doi-asserted-by":"publisher","first-page":"e0188100","DOI":"10.1371\/journal.pone.0188100","volume":"12","author":"A Virgone-Carlotta","year":"2017","unstructured":"Virgone-Carlotta A, Lemasson M, Mertani HC, Diaz JJ, Monnier S, Dehoux T, Delano\u00eb-Ayari H, Rivi\u00e8re C, Rieu JP. In-depth phenotypic characterization of multicellular tumor spheroids: effects of 5-Fluorouracil. PLoS ONE. 2017;12(11):e0188100.","journal-title":"PLoS ONE"},{"key":"7585_CR31","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ejpb.2022.10.003","volume":"180","author":"J Kroupov\u00e1","year":"2022","unstructured":"Kroupov\u00e1 J, Hanu\u0161 J, \u0160t\u011bp\u00e1nek F. Surprising efficacy twist of two established cytostatics revealed by a-la-carte 3D cell spheroid Preparation protocol. Eur J Pharm Biopharm. 2022;180:224\u201337.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"7585_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12885-017-3953-6","volume":"18","author":"CJ Lovitt","year":"2018","unstructured":"Lovitt CJ, Shelper TB, Avery VM. Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins. BMC Cancer. 2018;18(1):41.","journal-title":"BMC Cancer"},{"issue":"1","key":"7585_CR33","doi-asserted-by":"publisher","first-page":"18380","DOI":"10.1038\/s41598-023-45144-w","volume":"13","author":"ZN Abbas","year":"2023","unstructured":"Abbas ZN, Al-Saffar AZ, Jasim SM, Sulaiman GM. Comparative analysis between 2D and 3D colorectal cancer culture models for insights into cellular morphological and transcriptomic variations. Sci Rep. 2023;13(1):18380.","journal-title":"Sci Rep"},{"issue":"5","key":"7585_CR34","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.3390\/biomedicines11051484","volume":"11","author":"KN Ncube","year":"2023","unstructured":"Ncube KN, Jurgens T, Steenkamp V, Cromarty AD, van den Bout I, Cordier W. Comparative evaluation of the cytotoxicity of doxorubicin in BT-20 triple-negative breast carcinoma monolayer and spheroid cultures. Biomedicines. 2023;11(5):1484.","journal-title":"Biomedicines"},{"issue":"4","key":"7585_CR35","doi-asserted-by":"publisher","first-page":"788","DOI":"10.20517\/cdr.2023.93","volume":"6","author":"A Nikdouz","year":"2023","unstructured":"Nikdouz A, Orso F. Emerging roles of 3D-culture systems in tackling tumor drug resistance. Cancer Drug Resist. 2023;6(4):788.","journal-title":"Cancer Drug Resist"},{"issue":"5","key":"7585_CR36","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.3390\/ijms19051306","volume":"19","author":"CM Failla","year":"2018","unstructured":"Failla CM, Carbo M, Morea V. Positive and negative regulation of angiogenesis by soluble vascular endothelial growth factor receptor-1. Int J Mol Sci. 2018;19(5):1306.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"7585_CR37","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3390\/cells8101118","volume":"8","author":"CY Loh","year":"2019","unstructured":"Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, Chong PP, Looi CY. The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. Cells. 2019;8(10):1118.","journal-title":"Cells"},{"key":"7585_CR38","doi-asserted-by":"publisher","DOI":"10.4172\/2324-9110.1000185","author":"B Yashaswini","year":"2017","unstructured":"Yashaswini B, Mutahar A, Salimath BP. Anti-angiogenic activity of rTRAIL is potentiated by sFlt-1, a VEGF trap. J Clin Exp Oncol. 2017. https:\/\/doi.org\/10.4172\/2324-9110.1000185.","journal-title":"J Clin Exp Oncol"},{"issue":"40","key":"7585_CR39","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.2174\/1381612827666210902155015","volume":"27","author":"L Liao","year":"2021","unstructured":"Liao L, Zhao X, Zhou M, Deng Y, Li Y, Peng C. sFlt-1: A double regulator in angiogenesis-related diseases. Curr Pharm Design. 2021;27(40):4160\u201370.","journal-title":"Curr Pharm Design"},{"issue":"2","key":"7585_CR40","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/path.3018","volume":"226","author":"T Lechertier","year":"2012","unstructured":"Lechertier T, Hodivala-Dilke K. Focal adhesion kinase and tumor angiogenesis. J Pathol. 2012;226(2):404\u201312.","journal-title":"J Pathol"},{"issue":"12","key":"7585_CR41","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/emmm.201000106","volume":"2","author":"B Tavora","year":"2010","unstructured":"Tavora B, Batista S, Reynolds LE, Jadeja S, Robinson S, Kostourou V, Hart I, Fruttiger M, Parsons M, Hodivala-Dilke KM. Endothelial FAK is required for tumor angiogenesis. EMBO Mol Med. 2010;2(12):516\u201328.","journal-title":"EMBO Mol Med"},{"key":"7585_CR42","doi-asserted-by":"publisher","first-page":"175694","DOI":"10.1016\/j.ejphar.2023.175694","volume":"947","author":"J Zhang","year":"2023","unstructured":"Zhang J, Li W, Wang W, Chen Q, Xu Z, Deng M, Zhou L, He G. Dual roles of FAK in tumor angiogenesis: A review focused on pericyte FAK. Eur J Pharmacol. 2023;947:175694.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"7585_CR43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13293-018-0195-5","volume":"9","author":"AC Eddy","year":"2018","unstructured":"Eddy AC, Bidwell GL III, George EM. Pro-angiogenic therapeutics for preeclampsia. Biology Sex Differences. 2018;9(1):36.","journal-title":"Biology Sex Differences"},{"issue":"4","key":"7585_CR44","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jsps.2011.12.001","volume":"20","author":"LD Sasich","year":"2012","unstructured":"Sasich LD, Sukkari SR. The US FDAs withdrawal of the breast cancer indication for Avastin (bevacizumab). Saudi Pharm J. 2012;20(4):381\u20135.","journal-title":"Saudi Pharm J"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07585-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07585-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07585-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T01:02:56Z","timestamp":1767056576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07585-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7585"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07585-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"type":"electronic","value":"1479-5876"}],"subject":[],"published":{"date-parts":[[2025,12,20]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of financial interests or personal relationships.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1428"}}